**Supplementary File 1**

**Additional Reading**

* Lambert PA, Carraz G, Borselli S, Carbel S. Action neuro-psychotrope d’un nouvel anti-epileptique : le depamide. *Ann Med Psychol (Paris)* 1966 **124** : 707 – 710.
* Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I et al. Prescribing trends in bipolar disorder : cohort study in the United Kingdom THIN primary care database 1995-2009. *PloS One*, 2011 **6** : e28725. doi:10.1371/journal/pone.0028725.
* Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Mattoo SK, Basu D et al. Evaluation of psychotropic prescription patterns at the time of discharge from inpatient unit of a tertiary care general hospital psychiatric unit. *J Ment Health Human Behav*, 2016. **21** : 48 – 54.
* Wisner KL, Leckman-Westin E, Finnerty M, Essock SM. Valproate prescription prevalence among women of childbearing age. *Psychiatr Serv*, 2011, **62** : 281 – 220.
* Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller H-J et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders : update 2009 on the treatment of acute mania. *World J Biol Psychiat*, 2009, **10** : 85 – 116.
* Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar 1 disorder (BALANCE) : a randomised open-label trial. *Lancet*, 2010, 375 : 385 – 395.
* Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev*, (2013) Oct 17;(**10**): CD003196. Doi: 10:1002/14651858. CD003196.pub2.
* Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. *Am J Psychiatry*, 1975, **132** : 529 – 531.
* Giles JJ, Brannigan JG. Teratogenic and developmental effects of lithium. *Curr Pharm Des*, 2006, **12** : 1531 – 1541.
* Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects*. Lancet*, 1982, **2** : 937.
* Werler MM, Ahrens KA, Bosco JL, Mitchell AA, Anderka MT, Gilboa SM et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. *Ann Epidemiol*, 2011, **21** : 842 – 850.
* Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A et al. Dose-dependent risk of malformations with antiepileptic drugs : an analysis of data from the EURAP epilepsy and pregnancy registry. *Lancet Neurol* 2011, **10** : 609 – 617.
* Johannessen Landmark C, Burns ML, Baftiu A, Farmen AH, Lossius MI, Johannessen SI et al. Pharmacokinetic variability of valproate in women of childbearing age. *Epilepsia*, 2017, Oct; **58** (10) : e142 – e146. doi: 10.1111/epi.13872. Epub 2017 Aug 22.
* Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding : a systematic review and network meta-analysis. *BMJ Open*, 2017 : **7**:e017248. doi : 10.1136/bmjopen-2017-017248.
* Haskey C, Galbally M. Mood stabilisers in pregnancy and child development outcomes : a systematic review. *Aust N Zeal J Psychiat*, 2017, **51** : 1087 – 1097.
* Christensen J, Gronborg TK, Sorensen MJ, Schendel K, Parner ET, Pedersen LH et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*, 2013, **309** : 1696 – 1703.
* Cohen MJ, Meador KJ, Browning N, Baker GA, Clayton-Smith J, Kalayjian LA et al. Fetal antiepileptic drug exposure : motor, adatptive and emotional/behavioural functioning at age 3 years. *Epilepsy Behav*. 2011, **22** : 240 – 246.
* Boden R, Lundgren M, Brandt L, Reutfors J, Anderson M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder : population based cohort study. *BMJ*, 2012, **345**: e7085 doi: 10.1136.bmj.37085.
* James L, Paton C, Lelliott P, Barnes TRE, Taylor D. Mood stabilisers and teratogenicity – prescribing practice and awareness amongst practising psychiatrists*. J Ment Health*, 2009. **18** : 137 – 143.
* Paton C, Cookson J, Ferrier IN, Bhatti S, Fagan E, Barnes TRE. A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. *BMJ Open*, 2018, **8:**e020450. doi:10.1136/bmjopen-2017-020450.
* Drug Safety Update, volume **11**, issue 9 : April 2018 : 1.
* Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. Comparative efficacy and acceptability of antimanic drugs in acute mania : a multiple-treatments meta-analysis. *Lancet*, 2011, **378** : 1306 – 1315.
* Calaway K, Coshal S, Jones K, Coverdale J, Livingston R. A systematic review of the safety of electroconvulsive therapy use during the first trimester of pregnancy. *J ECT*, 2016, **32** : 230 – 235.
* Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R et al. Efficacy of valproate versus lithium in mania or mixed mania : a randomised, open 12-week trial. *Int J Psychopharmacol,* 2010, **25** : 60 – 67.
* Harrell NB, Teachey MK, Gifford NJ, Henriksen EJ. Essential role of p38 MAPK for activation of skeletal muscle glucose transport by lithium. *Arch Physiol Biochem*, 2007, **113** : 221 – 227.
* Tabata I, Schluter J, Guive EA, Holloszy JO. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. *Diabetes*, 1994, **43** : 903 – 907.
* Maison C, Bailly D, Peters AH, Quivy JP, Roche D, Taddel A et al. Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. *Nat Genet*. 2002, **30** : 329 – 334.
* Ganguly S, Seth S. A translational perspective on histone acetylation modulators in psychiatric disorders. *Psychopharmacology*, 2018, **235** : 1867 – 1873.
* Sun G, Jiang M, Zhou T, Guo Y, Cui Y, Guo X et al. Insights into the lysine acetylproteome of human sperm. *J Proteomics*, 2014, **109** : 199 – 211.
* Verrotti A, Loiacono G, Laus M, Coppola G, Chiarelli F, Tiboni GM. Hormonal and reproductive disturbances in epileptic male patients : emerging issues. *Reprod Toxicol*, 2011, **31** : 519 – 527.
* Isojarvi JI, Laatikainenl TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. *N Eng J Med*, 1993 : **329,** 1383 – 1388.
* Zhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder : a meta-analysis. *Eur J Obs Gynaecol Reprod Biol*, 2016, **202** : 26 – 31.
* Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH et al. Valproate is associated with new-onset oligoamenorrhea and hyperandrogenism in women with bipolar disorder. *Biol Psychiatry*, 2006 : **59** : 1078 – 1086.
* Talib HJ, Alderman EM. Gynaecologic and reproductive health concerns of adolescents using selected psychotropic medications. *Pediatr Adolesc Gynecol*, 2013, **26** : 7 – 15.